E
Cyclacel Pharmaceuticals, Inc.
CYCC
$0.269
-$0.0102-3.65%
E
Sell
3/26/2025Downgrade
Cyclacel Pharmaceuticals, Inc. (CYCC) was downgraded to E from E+ on 3/26/2025 due to a decline in the volatility index.
Cyclacel Pharmaceuticals, Inc. (CYCC) was downgraded to E from E+ on 3/26/2025 due to a decline in the volatility index.
E
Sell
3/11/2025Upgraded
Cyclacel Pharmaceuticals, Inc. (CYCC) was upgraded to E+ from E on 3/11/2025 due to an increase in the volatility index and total return index.
Cyclacel Pharmaceuticals, Inc. (CYCC) was upgraded to E+ from E on 3/11/2025 due to an increase in the volatility index and total return index.
E
Sell
2/10/2025Downgrade
Cyclacel Pharmaceuticals, Inc. (CYCC) was downgraded to E from E+ on 2/10/2025 due to a decline in the volatility index and total return index.
Cyclacel Pharmaceuticals, Inc. (CYCC) was downgraded to E from E+ on 2/10/2025 due to a decline in the volatility index and total return index.
E
Sell
1/24/2025Upgraded
Cyclacel Pharmaceuticals, Inc. (CYCC) was upgraded to E+ from E on 1/24/2025 due to an increase in the volatility index.
Cyclacel Pharmaceuticals, Inc. (CYCC) was upgraded to E+ from E on 1/24/2025 due to an increase in the volatility index.
E
Sell
1/7/2025Downgrade
Cyclacel Pharmaceuticals, Inc. (CYCC) was downgraded to E from E+ on 1/7/2025 due to a major decline in the solvency index, volatility index and total return index. The quick ratio declined from 0.97 to 0.67.
Cyclacel Pharmaceuticals, Inc. (CYCC) was downgraded to E from E+ on 1/7/2025 due to a major decline in the solvency index, volatility index and total return index. The quick ratio declined from 0.97 to 0.67.
E
Sell
3/14/2023Downgrade
Cyclacel Pharmaceuticals, Inc. (CYCC) was downgraded to E+ from D- on 3/14/2023 due to a decline in the volatility index.
Cyclacel Pharmaceuticals, Inc. (CYCC) was downgraded to E+ from D- on 3/14/2023 due to a decline in the volatility index.
D
Sell
3/9/2023Downgrade
Cyclacel Pharmaceuticals, Inc. (CYCC) was downgraded to D- from D on 3/9/2023 due to a noticeable decline in the growth index and solvency index. The quick ratio declined from 6.09 to 3.11, earnings per share declined from -$0.4179 to -$0.5957, and EBIT declined 36.77% from -$6.47M to -$8.85M.
Cyclacel Pharmaceuticals, Inc. (CYCC) was downgraded to D- from D on 3/9/2023 due to a noticeable decline in the growth index and solvency index. The quick ratio declined from 6.09 to 3.11, earnings per share declined from -$0.4179 to -$0.5957, and EBIT declined 36.77% from -$6.47M to -$8.85M.
D
Sell
2/9/2023Upgraded
Cyclacel Pharmaceuticals, Inc. (CYCC) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
Cyclacel Pharmaceuticals, Inc. (CYCC) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
E
Sell
2/8/2023Downgrade
Cyclacel Pharmaceuticals, Inc. (CYCC) was downgraded to E+ from D on 2/8/2023 due to a decline in the total return index.
Cyclacel Pharmaceuticals, Inc. (CYCC) was downgraded to E+ from D on 2/8/2023 due to a decline in the total return index.
D
Sell
11/18/2022Upgraded
Cyclacel Pharmaceuticals, Inc. (CYCC) was upgraded to D from D- on 11/18/2022 due to an increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.4563 to -$0.4179.
Cyclacel Pharmaceuticals, Inc. (CYCC) was upgraded to D from D- on 11/18/2022 due to an increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.4563 to -$0.4179.
D
Sell
8/15/2022Downgrade
Cyclacel Pharmaceuticals, Inc. (CYCC) was downgraded to D- from D on 8/15/2022 due to a noticeable decline in the growth index, total return index and volatility index. Earnings per share declined from -$0.42 to -$0.4563.
Cyclacel Pharmaceuticals, Inc. (CYCC) was downgraded to D- from D on 8/15/2022 due to a noticeable decline in the growth index, total return index and volatility index. Earnings per share declined from -$0.42 to -$0.4563.
D
Sell
5/16/2022Upgraded
Cyclacel Pharmaceuticals, Inc. (CYCC) was upgraded to D from E+ on 5/16/2022 due to an increase in the growth index. Earnings per share increased from -$0.5445 to -$0.42.
Cyclacel Pharmaceuticals, Inc. (CYCC) was upgraded to D from E+ on 5/16/2022 due to an increase in the growth index. Earnings per share increased from -$0.5445 to -$0.42.
E
Sell
5/13/2022Downgrade
Cyclacel Pharmaceuticals, Inc. (CYCC) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index and volatility index.
Cyclacel Pharmaceuticals, Inc. (CYCC) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index and volatility index.
D
Sell
5/4/2022Upgraded
Cyclacel Pharmaceuticals, Inc. (CYCC) was upgraded to D from E+ on 05/04/2022.
Cyclacel Pharmaceuticals, Inc. (CYCC) was upgraded to D from E+ on 05/04/2022.
E
Sell
5/1/2022Downgrade
Cyclacel Pharmaceuticals, Inc. (CYCC) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index and volatility index.
Cyclacel Pharmaceuticals, Inc. (CYCC) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index and volatility index.
D
Sell
4/21/2022Upgraded
Cyclacel Pharmaceuticals, Inc. (CYCC) was upgraded to D from E+ on 04/21/2022.
Cyclacel Pharmaceuticals, Inc. (CYCC) was upgraded to D from E+ on 04/21/2022.
E
Sell
4/20/2022Downgrade
Cyclacel Pharmaceuticals, Inc. (CYCC) was downgraded to E+ from D on 4/20/2022 due to a large decline in the total return index, growth index and volatility index. EBIT declined 8.94% from -$6M to -$6.53M, and earnings per share declined from -$0.5377 to -$0.5445.
Cyclacel Pharmaceuticals, Inc. (CYCC) was downgraded to E+ from D on 4/20/2022 due to a large decline in the total return index, growth index and volatility index. EBIT declined 8.94% from -$6M to -$6.53M, and earnings per share declined from -$0.5377 to -$0.5445.
D
Sell
11/17/2021Upgraded
Cyclacel Pharmaceuticals, Inc. (CYCC) was upgraded to D from D- on 11/17/2021 due to a noticeable increase in the growth index, total return index and solvency index. Earnings per share increased from -$0.5606 to -$0.5377, and EBIT increased 1.67% from -$6.1M to -$6M.
Cyclacel Pharmaceuticals, Inc. (CYCC) was upgraded to D from D- on 11/17/2021 due to a noticeable increase in the growth index, total return index and solvency index. Earnings per share increased from -$0.5606 to -$0.5377, and EBIT increased 1.67% from -$6.1M to -$6M.
D
Sell
11/8/2021Downgrade
Cyclacel Pharmaceuticals, Inc. (CYCC) was downgraded to D- from D on 11/8/2021 due to a decline in the growth index and valuation index. EBIT declined 41.7% from -$4.31M to -$6.1M, operating cash flow declined 18.2% from -$3.57M to -$4.22M, and earnings per share declined from -$0.497 to -$0.5606.
Cyclacel Pharmaceuticals, Inc. (CYCC) was downgraded to D- from D on 11/8/2021 due to a decline in the growth index and valuation index. EBIT declined 41.7% from -$4.31M to -$6.1M, operating cash flow declined 18.2% from -$3.57M to -$4.22M, and earnings per share declined from -$0.497 to -$0.5606.
D
Sell
5/1/2020Upgraded
Cyclacel Pharmaceuticals, Inc. (CYCC) was upgraded to D from D- on 5/1/2020 due to an increase in the volatility index and total return index.
Cyclacel Pharmaceuticals, Inc. (CYCC) was upgraded to D from D- on 5/1/2020 due to an increase in the volatility index and total return index.
D
Sell
11/15/2019Upgraded
Cyclacel Pharmaceuticals, Inc. (CYCC) was upgraded to D- from E+ on 11/15/2019 due to an increase in the efficiency index.
Cyclacel Pharmaceuticals, Inc. (CYCC) was upgraded to D- from E+ on 11/15/2019 due to an increase in the efficiency index.
E
Sell
8/19/2019Downgrade
Cyclacel Pharmaceuticals, Inc. (CYCC) was downgraded to E+ from D- on 8/19/2019 due to a large decline in the growth index, volatility index and solvency index. The quick ratio declined from 7.79 to 6.75, and EBIT declined 6.03% from -$2.2M to -$2.34M.
Cyclacel Pharmaceuticals, Inc. (CYCC) was downgraded to E+ from D- on 8/19/2019 due to a large decline in the growth index, volatility index and solvency index. The quick ratio declined from 7.79 to 6.75, and EBIT declined 6.03% from -$2.2M to -$2.34M.
D
Sell
3/11/2016Downgrade
Cyclacel Pharmaceuticals, Inc. (CYCC) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index and total return index.
Cyclacel Pharmaceuticals, Inc. (CYCC) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index and total return index.
NASDAQ
04/01/2025 4:00PM Eastern
Quotes delayed
